1. Wu H. China approves another covid-19 vaccine for emergency use. AP. 16 March 2021. https://apnews.com/article/science-biology-clinical-trials-microbiology-coronavirus-pandemic-25b1d6227a0921038a0dbded2c7dfb6c.
2. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
3. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
4. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
5. Sinopharm’s covid-19 vaccine 79% effective, seeks approval in China. Reuters. 30 December 2020. www.reuters.com/article/health-coronavirus-china-vaccine-int-idUSKBN2940CA.